Recent publications published by researchers at the MRC WIMM.
Screening for and surveillance of premalignant conditions of the stomach
Luzko I. et al, (2025), Best Practice and Research: Clinical Gastroenterology
The road to a world-unified approach to the management of patients with gastric intestinal metaplasia: a review of current guidelines.
Dinis-Ribeiro M. et al, (2024), Gut, 73, 1607 - 1617
Update S2k-Guideline Helicobacter pylori and gastroduodenal ulcer disease of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS).
Fischbach W. et al, (2024), Z Gastroenterol, 62, 261 - 321
Liver cirrhosis is a risk-factor for Pneumocystis jirovecii associated mortality
Peschel G. et al, (2024), Frontiers in Medicine, 11
Letter to the editor: Helicobacter pylori eradication - the proof is not in the symptoms.
Bornschein J. et al, (2023), Gut, 72, 2387 - 2388
Low-cost and clinically applicable copy number profiling using repeat DNA.
Abujudeh S. et al, (2022), BMC Genomics, 23
Myths and misconceptions in the management of Helicobacter pylori infection
Bornschein J. and Mark Pritchard D., (2022), Frontline Gastroenterology, 13, 245 - 253
The Role of Microbiota in Gastrointestinal Cancer and Cancer Treatment: Chance or Curse?
Smet A. et al, (2022), Cellular and molecular gastroenterology and hepatology, 13, 857 - 874
A Pilot Study on Automatic Three-Dimensional Quantification of Barrett's Esophagus for Risk Stratification and Therapy Monitoring.
Ali S. et al, (2021), Gastroenterology, 161, 865 - 878.e8
EGF and BMPs Govern Differentiation and Patterning in Human Gastric Glands.
Wölffling S. et al, (2021), Gastroenterology, 161, 623 - 636.e16
Author Correction: A dynamic CD2-rich compartment at the outer edge of the immunological synapse boosts and integrates signals.
Demetriou P. et al, (2021), Nat Immunol, 22
A dynamic CD2-rich compartment at the outer edge of the immunological synapse boosts and integrates signals.
Demetriou P. et al, (2020), Nat Immunol, 21, 1232 - 1243
Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial.
Fitzgerald RC. et al, (2020), Lancet, 396, 333 - 344
Identification of Subtypes of Barrett's Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data.
Jammula S. et al, (2020), Gastroenterology, 158, 1682 - 1697.e1
Adenocarcinoma of the Stomach and Other Gastric Tumors
Quante M. and Bornschein J., (2020), Sleisenger and Fordtran's Gastrointestinal and Liver Disease-2 Volume Set, 11th Edition: Pathophysiology, Diagnosis, Management, 820 - 841.e13
Development and validation of a risk prediction model to diagnose Barrett's oesophagus (MARK-BE): a case-control machine learning approach.
Rosenfeld A. et al, (2020), Lancet Digit Health, 2, E37 - E48
Patient-specific cancer genes contribute to recurrently perturbed pathways and establish therapeutic vulnerabilities in esophageal adenocarcinoma.
Mourikis TP. et al, (2019), Nat Commun, 10
Clonal Diaspora in Metastatic Esophageal Adenocarcinoma Describes a New Model of Cancer Progression
Noorani A. et al, (2019), SSRN Electronic Journal